A B S T R A C T To investigate serum requirements for optimal erythropoiesis in vitro, we studied the response of erythroid progenitor cell proliferation in culture to platelet-derived growth factor (PDGF). Human bone marrow cells cultured with platelet-poor plasma-derived serum (PDS) form fewer erythroid colonies than do cells cultured with human whole blood serum or fetal calf serum (P < 0.05). Treatment of washed platelets with thrombin releases a low molecular weight (<100,000) factor that enhances colony growth. This secreted factor appears to be PDGF, based upon the ability of partially purified and electrophoretically pure PDGF to restore colony-forming capacity of PDScontaining cultures to 70-96% of the level found in control cultures with whole blood serum or fetal calf serum. Enhancement of colony growth by PDGF was noted only in marrow cultures supplemented with erythropoietin and PDS. Presence of bioactive erythropoietin in PDGF preparations was excluded by assay in hypertransfused, polycythemic mice, and in fasted rats. Although PDGF stimulates erythroid burst formation in marrow cultures containing optimal concentrations of burst-promoting activity (BPA), it does not influence proliferation of circulating erythroid bursts, regardless of BPA concentration added to culture. We conclude that PDGF is a serum determinant of optimal erythroid progenitor cell proliferation in marrow culture. The activity of PDGF is distinct from that of the apparent erythroid specific growth factors erythropoietin and BPA.
A B S T R A C T To investigate serum requirements for optimal erythropoiesis in vitro, we studied the response of erythroid progenitor cell proliferation in culture to platelet-derived growth factor (PDGF). Human bone marrow cells cultured with platelet-poor plasma-derived serum (PDS) form fewer erythroid colonies than do cells cultured with human whole blood serum or fetal calf serum (P < 0.05). Treatment of washed platelets with thrombin releases a low molecular weight (<100,000) factor that enhances colony growth. This secreted factor appears to be PDGF, based upon the ability of partially purified and electrophoretically pure PDGF to restore colony-forming capacity of PDScontaining cultures to 70-96% of the level found in control cultures with whole blood serum or fetal calf serum. Enhancement of colony growth by PDGF was noted only in marrow cultures supplemented with erythropoietin and PDS. Presence of bioactive erythropoietin in PDGF preparations was excluded by assay in hypertransfused, polycythemic mice, and in fasted rats. Although PDGF stimulates erythroid burst formation in marrow cultures containing optimal concentrations of burst-promoting activity (BPA), it does not influence proliferation of circulating erythroid bursts, regardless of BPA concentration added to culture. We conclude that PDGF is a serum determinant of optimal erythroid progenitor cell proliferation in marrow culture. The activity of PDGF is distinct from that of the apparent erythroid specific growth factors erythropoietin and BPA. INTRODUCTION Erythroid progenitors known as colony-forming unitserythroid (CFU-E)' and burst-forming units-erythroid (BFU-E, or bursts) can be assayed by their in vitro capacity to proliferate in response to tissue-specific regulators such as erythropoietin and burst-promoting activity (1) . It is believed that mammalian serum provides an appropriate balance of nutritional factors essential for optimal colony formation (1-3). For example, albumin, transferrin, iron, and a variety of lipids must be present at critical concentrations for CFU-E proliferation to occur in serum-free cultures (4, 5) . In addition, serum may contain peptide hormones or hormonelike growth factors that are required for optimal erythroid cell proliferation (6) (7) (8) .
Recently, platelet-derived growth factor (PDGF), a low molecular weight platelet secretory protein, has been shown to stimulate the division of several different types of mammalian cells in culture (9) (10) (11) . To determine whether PDGF may be an important serum factor for proliferation of erythropoietic progenitor cells, we have measured the effect of secreted platelet products and of purified PDGF on the proliferation of CFU-E and BFU-E derived from human bone marrow. We have found that colony growth is significantly enhanced by whole blood serum (WBS) in comparison to platelet-poor plasma-derived serum (PDS). The stimulatory factor is a heat-stable, low molecular weight material released by thrombin treatment of washed platelets. Since partially purified and electrophoretically pure PDGF significantly enhance ery-throid colony formation, we suggest that PDGF is a serum determinant of optimal CFU-E and BFU-E proliferation by bone marrow cells in vitro.
METHODS
Preparation of WBS and PDS. WBS and PDS were prepared by the method of Vogel et al. (12, 13) . Briefly, fresh blood was obtained from normal AB-positive volunteers with informed consent and approval of an Institutional Review Board. Blood was mixed in plastic tubes with one-ninth volume of 3.8% sodium citrate and divided into two equal portions. One portion of blood was clotted by addition of oneseventieth volume of 1 M CaCI2, followed by incubation for 2 h at 370C and centrifugation at 1,100 g for 15 min at 40C. The resulting WBS was recentrifuged at 31,000 g for 30 min to remove any residual platelets and then was dialyzed for 1-2 d against large volumes of 140 mM NaCl, 10 mM sodium phosphate, pH 7.4 (phosphate-buffered saline, PBS). In some experiments, the WBS was concentrated severalfold after dialysis by use of Sephadex G-200 around the dialysis bag. After heating at 560C for 30 min, the dialyzed solution was centrifuged at 31,000 g for 30 min at 40C. The supernatant solution was sterilized by passage through a 0.45-,gm Millipore filter (Millipore Corp., Bedford, MA) and stored at 4°o r -20'C until use. For preparation of PDS, the second portion of citrate-anticoagulated blood was centrifuged at 1,100 g for 20 min at 40C. The plasma was recentrifuged at 31,000 g for 20 min and then clotted by addition of one-fiftieth volume of 1 M CaC12. Subsequent processing was identical to that described for preparation of WBS.
Isolation of platelet secretory products. Platelet concentrates from one or two pheresis donors (8-21 U) were obtained from the American Red Cross Blood Services, Boston, MA within 36 h of donation. A one-fourth volume of anticoagulant acid citrate dextrose (ACD National Institutes of Health formula A) was added, and the platelets were pelleted by centrifugation at 900 g for 15 min. The platelets were resuspended in 0.02 M Tris-HCI (pH 7.6), 0.15 M NaCI, 5 mM glucose and 10% ACD; centrifuged at 200 g for 6 min to remove contaminating erythrocytes and leukocytes; and then washed three times in the same buffer. The platelets were then resuspended in Tris-buffered saline without ACD (4 ml/U) and the pH was readjusted to pH 7.6, if necessary, prior to the addition of 1 U/ml of purified human thrombin (provided by Dr. J. Fenton II) to the stirred platelet suspension at 37°C. After 2 min, 2 U of hirudin (Pentapharm, Switzerland)/ml of platelet suspension was added, and the aggregates were allowed to settle. EDTA was added to bring the supernatant to 1 mM. After decantation and centrifugation at 20,000 g for 20 min, the sample was applied to a column (5 X 90 cm) of Sepharose 4B equilibrated with 0.02 M Tris-HCl (pH 7.6), 0.15 M NaCl and 1 mM EDTA at 4°C. The column fractions were analyzed for total protein by the method of Lowry et al. (14) , using bovine serum albumin (BSA) as the standard, and for platelet factor 4 and fl-thromboglobulin-related antigen by radioimmunoassay kits prepared by Abbott Laboratories, North Chicago, IL and Amersham Corp., Arlington Heights, IL, respectively. Thrombospondin was purified from the supernatant of a thrombin-treated platelet suspension by heparin-Sepharose affinity chromatography in the presence of 1 mM EDTA, as described previously (15) .
Preparation of crude platelet extracts by heat treatment or sonication. Heat-treated platelet extracts were prepared by a modification of the method of Antoniades et al. (10) .
Platelets from concentrates were washed twice with a solution containing 9 vol of 150 mM NaCl, 17 Russel Ross (17) and of Dr. Charles D. Stiles (18) . The former sample was dissolved in 1 mM acetic acid and diluted in PBS plus bovine serum albumin (BSA) at a final BSA concentration of 2 mg/ml. The latter sample containing 0.1 mg/ml BSA was diluted in NCTC-109. 100 ul of purified PDGF were added to culture to produce final concentrations of 10-5 to 1 ng/ml. Concurrently run controls for each marrow culture contained 100 Ml of NCTC-109. Stimulation was calculated as percentage of growth in cultures to which NCTC-109 alone was added to the culture mixture. Preparation and assay of conditioned media (CM). Serum-free conditioned medium was prepared with 150 ml of peripheral blood from a healthy donor that was collected into a-medium containing 20 U/ml heparin. Mononuclear cells separated over Ficoll-Paque were mixed for 20 min with a carbonyl iron suspension (Technicon Instruments Corp., Tarrytown, NY) and separated again over FicollPaque to deplete them of macrophages. Greater than 98% of the interface cells were nonspecific esterase negative. They were washed three times in a-medium and resuspended at a d 5 X 106/ml in tissue culture flasks in a-medium with L-glutamine, streptomycin, and penicillin (Gibco Laboratories). CM was harvested after 24 h of incubation at 370C, 4% CO2 and freed of cells by centrifugation at 280 g for 20 min. Greater than 98% of the cells excluded trypan blue. Control medium was incubated in the absence of cells. Burst-promoting activity (BPA) present in CM was assayed as previously described (19) in marrow or peripheral blood cultures containing 4.5% PDS. CM was added at final concentrations of 0.0, 0.9, 4.5, 9.0, 13.5, 18.0, or 27.0% (vol/vol) in the presence and absence of 0.01 ng/ml purified PDGF. Colony growth was compared to that observed in cultures concurrently established with 27% FCS and no added CM or PDGF.
Statistical analysis. The mean±1 SEM colonies formed in quadruplicate cultures was determined and data sets were compared by the two sample ranks test of Wilcoxon-White (20) , unless otherwise stated.
Assays for in vivo erythropoietin activity. Since it is possible that platelet secretory products have erythropoietic stimulatory activity similar to that of erythropoietin, we assayed PDS, WBS, and a partially purified PDGF for in vivo erythropoietin bioactivity in plethoric animals using two assay systems. In the first, 0.5 ml of test material, isotonic saline or sheep step III erythropoietin standards were injected subcutaneously on two consecutive days into each of five hypertransfused, polycythemic CF1 mice (Cartworth Laboratories, Woburn, MA). Mice with hematocrits < 55% were excluded from the assay. 24 h later, 59Fe was injected intravenously, and radioactive iron incorporated into circulating erythrocytes after 24 h was determined, according to the method of Shadduck, Howard, and Stohlman (21) .
The erythropoietin activity in each sample was then determined by comparing radioactivity in samples from test animals with that from animals injected with standard materials (mean percent 59Fe incorporations of 0.01, 0.63, 1.78, and 2.95 for normal saline and 0.25, 0.50, and 1.00 IU/ml erythropoietin, respectively). In our laboratory, <0.025 IU/ ml is detected in normal human serum. In the second assay system, rats were fasted for 60 h and then injected with 0.5 ml test or standard material as above. Those with hematocrits < 40% were excluded from the assay. 59Fe was injected as above and radioactive iron incorporation was determined (21) . Mean percent 59Fe incorporations of 1.88, 5.97, 17.69, and 19.19 were determined in samples from rats injected with normal saline or with 0.50, 1.00, or 1.50 IU/ml erythropoietin, respectively. In our hands, activity of > 0.5 IU/ ml may be detected by this method.
RESULTS
Support of colony growth by WBS or PDS. As shown in Fig. 1 , relative to colony formation in WBS containing cultures, colonies were reduced at all PDS concentrations tested (P < 0.05). CFU-E and BFU-E proliferations in cultures containing 27% PDS were only 28 and 15%, respectively, of growth in conventional cultures containing 27% FCS (P < 0.01). In contrast, erythroid colony growth in cultures containing 27% WBS was similar to growth in cultures containing In addition, washed platelets were alternately frozen and thawed and either incubated at 1000C for 10 min or sonicated. To determine whether stimulatory products were released, supernatants were then added to culture. We found them to contain colony stimulatory activity (see Table 1 ), thereby confirming our observation that platelet-derived products contain growthpromoting activity.
Effects of partially purified PDGF on colony growth. We next tested a partially purified PDGF preparation for erythroid colony stimulatory activity. Fig. 3 demonstrates that this preparation of PDGF at final total protein concentrations of 0.015 to 150 ng/ml stimulated both CFU-E-and BFU-E-derived colony growth (P < 0.01 for differences in outcomes at the optimal concentrations of 1.5 and 15 ng/ml). PDGF concentrations of 1,500 ng/ml or greater inhibited colony formation. As anticipated, no growth enhancement was observed when PDS or the high molecular weight platelet glycoprotein thrombospondin was tested (see Fig. 3 ). Optimal PDGF concentrations also stimulated colony proliferation at erythropoietin doses of 0.1, 0.5, 1, and 4 IU/ml (data not shown). No colonies formed in the absence of added erythropoietin.
Not only the number, but also the size of erythroid colonies was increased by PDGF. While two-thirds of CFU-E derived colonies in control cultures with NCTC-109 consisted of between 8 Since it is possible that PDGF may be the critical serum growth factor, we tested varying PDGF concentrations in cultures containing no other serum constituent. Fig. 4 shows that no colonies formed in serumfree cultures containing partially purified PDGF. We also assayed colony growth in cultures with varying concentrations of PDS and a constant amount of PDGF. Increasing concentrations of PDS were associated with higher numbers of CFU-E derived colonies (see Fig. 4 ). Colony growth in cultures with PDS and PDGF was similar to that in WBS-containing cultures (P > 0.10) at all serum concentrations. Similar effects were observed for BFU-E proliferation (data not shown).
Colony stimulation by purified PDGF. To confirm that PDGF is a growth-promoting factor, we added various concentrations of electrophoretically pure PDGF to PDS-containing cultures. As shown in Fig.  5 Table II ). Interaction of PDGF with BPA. To assess the possibility that PDGF activity can replace that of the growth factor erythroid BPA, we measured PDGF effects in marrow and peripheral blood cultures containing various amounts of CM. Fig. 6 shows that when added to marrow cultures containing 4.5% PDS, 0.01 ng/ml of purified PDGF stimulated colony growth at both suboptimal and optimal (29.0%) CM concentrations. The level to which PDGF augmented burst formation in serum-restricted cultures was reduced to approximately one-half of that observed in cultures containing 27% PDS; this reduction was corrected by the addition of CM (see Fig. 6 ). Table II shows that erythroid progenitor cells (6, 7) . Several investigators have proposed that serum is a pathological rather than physiological fluid and that, in addition to these growth factors, it may contain numerous mitogenic molecules released from platelets (9) (10) (11) (12) (13) . In this communication we show that WBS, but not PDS contains a colonypromoting activity for human bone marrow BFU-E and CFU-E. Furthermore, treatment of platelets with thrombin is associated with the release of a factor having mitogenic activity for erythroid progenitors or for other cells that in turn may interact with progenitors in vitro. This activity comigrates with molecules having a molecular weight of <100,000. Studies with partially purified and electrophoretically pure PDGF suggest that PDGF most likely accounts for this growth promoting activity.
While the mechanism by which PDGF augments erythropoiesis is not known, several conclusions may be drawn from our observations. First, since erythroid colonies do not appear in erythropoietin-deprived cultures, even if WBS or PDGF is added, the action of PDGF cannot replace that of erythropoietin in bone marrow culture. Moreover, PDGF has no in vivo effect on 59Fe incorporation in the polycythemic mouse assay and, therefore, does not mimic the bioactivity of erythropoietin. Next, the colony stimulatory effect of PDGF is dependent upon the presence of not only erythropoietin but also other factors found in plasma. The latter finding is consistent with the observation that PDGF and plasma constituents may act coordinately in stimulation of cell division of other cell types (12) . Finally, because there is a similar growth enhancing effect when PDGF is assayed with optimal or suboptimal BPA concentrations, and since CFU-E derived growth is also stimulated by PDGF, it appears that PDGF activity cannot supplant BPA in vitro. Thus, PDGF is an erythropoietic growth factor that is distinct from apparent erythroid specific growth factors such as erythropoietin and BPA. Its modes of induction of mitogenesis and its interactions with erythropoietin and other private as well as public growth factors present in plasma require definition.
The proliferation of both BFU-E and CFU-E in the bone marrow is increased by PDGF, indicating that the state of differentiation of the marrow stem cell is not a critical factor for this erythropoietic effect. Our 
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N. Dainiak, C. Davies, M.Kalmanti, J. Lawler, and V. Kulkarni finding that purified PDGF augments colony growth in a saturable fashion agrees with observations regarding the action of this growth factor (12) . In contrast, circulating BFU-E proliferation is unaffected by PDGF. We may speculate that the target cell of PDGF is present in mononuclear cells prepared from bone marrow but is absent from or reduced in those prepared from peripheral blood. Alternatively, it is possible that diminished PDGF binding may explain differences in mitogenic response or that circulating stem cells themselves are qualitatively different from marrow stem cells with respect to PDGF action.
In conclusion, our data suggest that platelets may play a role in the regulation of normal in vitro erythropoietic differentiation by their release of PDGF. Other platelet-derived factors with mitogenic activity for connective tissue cells in culture may also have erythropoietic activity (17, 22, 23) . While various serum growth factors, including erythropoietin and BPA, may be essential for in vitro erythropoiesis, optimal proliferation requires the presence of plateletderived molecules. It is not known whether a similar requirement exists for optimal erythropoiesis in vivo. However, it is now recognized that cellular interactions are important in the regulation of erythropoiesis and that fibroblasts and smooth muscle cells are physically associated with multiple levels of erythroid differentiation within the local environment of mammalian bone marrow (24) (25) (26) . Since PDGF augments DNA synthesis and division of mesenchymal cells (27, 28 ) that may in turn stimulate erythropoiesis (29) , it is possible that the erythropoietic activity of PDGF may be due to replacement of growth factors for nonerythroid cells that are normally present in bone marrow in vivo. On the other hand, PDGF may replace factors that are mitogenic either for hematopoietic cells in general or for specific erythroid progenitor cell populations. Studies using purified PDGF to obtain hematopoietic populations that are enriched in progenitor cells may elucidate the characteristics of target cells that are required for an erythropoietic effect.
